Bisoprolol (Concor, bisotrol) is a selective Beta-1 receptor inhibitor that selectively and competitively blocks the Beta-1 receptors without affecting the Beta-2 receptors especially at doses of less than 20 mg per day. It is one of the WHO's lists of essential medicine and is used to treat the following conditions:
-
Management of hypertension (Not recommended as first-line of therapy)
-
Off Label Use of Bisoprolol in Adults include:
-
Acute Myocardial infarction
-
For rate control in atrial fibrillation
-
Heart failure with a reduced ejection fraction
-
Ventricular arrhythmias
-
Chronic stable angina
-
Supraventricular arrhythmias.
-
Bisoprolol dose in adults:
-
Bisoprolol as off-label use in the treatment of Atrial fibrillation (for rate control):
- 2.5 - 10 mg once a day.
-
Off-label use in the treatment of Heart failure with a reduced ejection fraction:
- 1.25 mg orally once a day.
- The dose may be doubled every 2 weeks or more to the maximum tolerated dose (the maximum dose should not exceed 10 mg/day.
- Bisoprolol therapy should be initiated only once the patient is stable, the volume status is optimized, inotropes, vasopressors, and intravenous diuretics have been discontinued.
-
Use as an alternative agent in Hypertension:
- 2.5 - 5 mg orally once a day.
- The dose may be titrated to a maximum dose of 20 mg once a day.
- The usual dose ranges between 2.5 - 10 mg once a day.
-
Off label use in the treatment of Ventricular arrhythmias:
- 5 - 10 mg orally once a day.
Bisoprolol for anxiety:
- 2.5 - 5 mg once daily
Bisoprolol Dose in Children
- Not recommended for use in children.
Pregnancy Risk Factor C
- Bisoprolol has been linked to fetal bradycardia, hypoglycemia and a decreased birth weight.
- However, maternal hypertension can also lead to adverse maternal and fetal outcomes.
- Like other beta-blockers such as bisoprolol in pregnancy, it can be used to treat hypertension and heart failure. However, you should first consider other agents.
Bisoprolol use during breastfeeding:
- It is unknown if bisoprolol can be absorbed into breastmilk.
- You should be cautious when using it in nursing women.
- Patients with peripartum cardiomyopathy should not breastfeed.
Bisoprolol Dose in Renal Disease:
-
For the treatment of hypertension:
- CrCl of 40 mL/minute or more:
- No dose adjustment is required as per the manufacturer's labeling.
- CrCl of less than 40 mL/minute:
- 2.5 mg once a day.
- Increase the drug with caution.
- CrCl of 40 mL/minute or more:
-
For the treatment of Heart failure as off-label use:
- Data is less available. On the other hand, starting doses range from 1.25 mg once daily to 2.5 mg once daily.
-
Hemodialysis:
- It is not dialyzable.
Bisoprolol Dose in Liver Disease:
-
Bisoprolol Dose in Chronic liver disease:
- 2.5 mg once a day.
- The dose may be increased cautiously.
Common Bisoprolol Side Effects Include:
-
Cardiovascular:
- Chest Pain
-
Central Nervous System:
- Fatigue
- Hypoesthesia
-
Gastrointestinal:
- Diarrhea
- Vomiting
-
Hepatic:
- Increased Serum Alanine Aminotransferase
- Increased Serum Aspartate Aminotransferase
-
Respiratory:
- Upper Respiratory Tract Infection
- Dyspnea
Bisoprolol side effects (rare):
-
Cardiovascular:
- Cardiac Arrhythmia
- Cardiac Failure
- Claudication
- Cold Extremities
- Edema
- Flushing
- Hypersensitivity Angiitis
- Hypotension
- Orthostatic Hypotension
- Palpitations
-
Central Nervous System:
- Anxiety
- Depression
- Dizziness
- Drowsiness
- Headache
- Hyperesthesia
- Insomnia
- Lack Of Concentration
- Malaise
- Memory Impairment
- Paresthesia
- Restlessness
- Sensation Of Eye Pressure
- Twitching
- Vertigo
- Vivid Dream
-
Dermatologic:
- Acne Vulgaris
- Alopecia
- Diaphoresis
- Eczema
- Pruritus
- Skin Irritation
- Skin Rash
-
Endocrine & Metabolic:
- Decreased Libido
- Gout
- Increased Serum Glucose
- Increased Serum Phosphate
- Increased Serum Potassium
- Increased Serum Triglycerides
- Increased Uric Acid
- Weight Gain
-
Gastrointestinal:
- Abdominal Pain
- Constipation
- Dysgeusia
- Dyspepsia
- Epigastric Pain
- Gastric Pain
- Gastritis
- Nausea
- Peptic Ulcer
- Xerostomia
-
Genitourinary:
- Cystitis
- Impotence
-
Hematologic & Oncologic:
- Decreased White Blood Cell Count
- Positive ANA Titer
- Purpuric Rash
- Thrombocytopenia
-
Neuromuscular & Skeletal:
- Back Pain
- Muscle Cramps
- Myalgia
- Neck Pain
- Tremor
-
Ophthalmic:
- Abnormal Lacrimation
- Eye Pain
- Visual Disturbance
-
Otic:
- Otalgia
- Tinnitus
-
Renal:
- Increased Blood Urea Nitrogen
- Increased Serum Creatinine
- Polyuria
- Renal Colic
-
Respiratory:
- Asthma
- Bronchitis
- Bronchospasm
- Cough
- Dyspnea On Exertion
- Pharyngitis
- Rhinitis
- Sinusitis
Contraindication to Bisoprolol include:
- Cardiogenic shock
- Overt heart failure
- Sinus bradycardia marked
- Heart block of second or third degree
- Allergic reaction to the drug
Warnings and Precautions
- Anaphylactic reactions
- It has been associated with severe allergic reactions, including anaphylaxis.
- Patients being treated for anaphylaxis might not respond to epinephrine while on beta-blocker therapy.
- Bronchospastic disease
- Patients with an allergic airway disease should not use Beta-blockers.
- If used, the lowest possible dose should be advised and an inhaled Beta-1 agonist therapy should be available for immediate relief if the condition worsens.
- Asthmatics should not take more than 20 mg of bisoprolol daily.
- Conductive abnormality
- Patients suffering from sick sinus syndrome should not receive beta-blockers.
- Diabetes:
- It can increase hypoglycemia and mask hypoglycemia symptoms in diabetic patients.
- Heart failure:
- Patients with compensated cardiac failure should use it with caution.
- Low doses of therapy should be used and patients should be closely monitored.
- Hepatic impairment
- Patients with severe liver disease should be cautious.
- Patients with severe hepatic impairment may need to adjust their dose.
- Myasthenia gravis:
- Patients with myasthenia gravis should be careful when using bisoprolol.
- Raynaud and peripheral vascular disease (PVD).
- In patients with Raynaud's disease and peripheral vascular disease, it can exacerbate the signs and symptoms of arterial dysfunction.
- Monitor your patient for any worsening symptoms while on beta-blocker therapy.
- Pheochromocytoma:
- A sufficient amount of alpha-blockade must be achieved before you can start therapy with a beta blocker.
- Angina Prinzmetal version:
- Patients with Prinzmetal variant Angina should not be treated with beta-blockers that do not block alpha1adrenergic receptor activity.
- This might aggravate anginal symptoms by causing coronary vasoconstriction.
- Psoriasis:
- Beta-blockers can cause psoriasis patients to experience worsening symptoms.
- Renal impairment
- Patients who use the medication should exercise caution if they have poor renal function.
- If the CrCl level is below 40 ml/min, adjustments may be necessary in the dosage.
- Thyroid disease:
- It can mask hyperthyroidism symptoms.
- Patients with hyperthyroidism should not abruptly stop taking beta-blockers as this could lead to a thyroid storm.
Bisoprolol: Drug Interaction
|
Acetylcholinesterase Inhibitors |
May enhance the bradycardic effect of Beta-Blockers. |
|
Alfuzosin |
May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
|
Alpha1-Blockers |
Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1Blockers. The risk associated with ophthalmic products is probably less than systemic products. |
|
Aminoquinolines (Antimalarial) |
Beta-Blockers' metabolism might be slowed down. |
|
Amiodarone |
Could make beta-blockers' bradycardic impact stronger. It could have reached the point of cardiac arrest. Beta-Blockers' serum concentration may rise as a result of amiodarone. |
|
Amphetamines |
May lessen the effectiveness of antihypertensive agents. |
|
Antipsychotic Agents (Phenothiazines) |
May strengthen beta-blockers' hypotensive effects. Antipsychotic Agents' metabolism may be slowed down by beta-blockers (Phenothiazines). Phenothiazines, or antipsychotic agents, may slow down the metabolism of beta-blockers. |
|
Antipsychotic Agents (Second Generation [Atypical]) |
Antipsychotic drugs' hypotensive effects may be enhanced by blood pressure-lowering medications (Second Generation [Atypical]). |
|
Barbiturates |
May lower the level of beta-blockers in the serum. |
|
Barbiturates |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Benperidol |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Beta2-Agonists |
The bronchodilatory impact of beta2-agonists may be lessened by beta-blockers (beta1 selective). Particular attention should be paid to nonselective beta-blockers or beta1 selective beta-blockers at larger doses. |
|
Bosentan |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). |
|
Bradycardia-Causing Agents |
May intensify other bradycardia-causing agents' bradycardic effects. |
|
Bretylium |
Bradycardia-Causing Agents' bradycardic effect might be enhanced. In patients taking AV blocking medications, bretylium may also strengthen atrioventricular (AV) blockade. |
|
Brigatinib |
May lessen the effectiveness of antihypertensive agents. Antihypertensive Agents' bradycardic action may be strengthened by brutinib. |
|
Brimonidine (Topical) |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Bupivacaine |
Beta-blockers may raise the serum level of buprenorphine. |
|
Calcium Channel Blockers (Nondihydropyridine) |
May strengthen betablockers' hypotensive effects. In addition, reports of bradycardia and heart failure symptoms have been made. The serum concentration of beta-blockers may rise in response to calcium channel blockers (nondihydropyridine). Bepridil is an exception. |
|
Cardiac Glycosides |
Cardiac Glycosides' bradycardic action may be strengthened by beta-blockers. |
|
Cholinergic Agonists |
Beta-Blockers may make Cholinergic Agonists' harmful or toxic effects worse. The possibilities for bronchoconstriction and aberrant cardiac conduction are of special concern. Management: Use cautious while combining these drugs, and keep an eye out for conduction issues. Because methacholine may cause further bronchoconstriction when used with any beta blocker, avoid using it. |
|
CYP3A4 Inducers (Moderate) |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). |
|
Deferasirox |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). |
|
Dexmethylphenidate |
Decrease the therapeutic benefit of antihypertensive drugs. |
|
Diazoxide |
BP lowering medications may have an enhanced hypotensive effect. |
|
Dipyridamole |
Beta-Blockers' bradycardic impact could be boosted. |
|
Disopyramide |
Beta-Blockers' bradycardic impact could be boosted. Beta-blockers may intensify Disopyramide's unfavourable inotropic impact. |
|
DULoxetine |
DULoxetine's hypotensive impact may be enhanced by blood pressure-lowering medications. |
|
EPINEPHrine (Nasal) |
Epinephrine's therapeutic impact may be reduced by beta-blockers (Beta1 Selective) (Nasal). |
|
EPINEPHrine (Oral Inhalation) |
Epinephrine's therapeutic impact may be reduced by beta-blockers (Beta1 Selective) (Oral Inhalation). |
|
Epinephrine (Racemic) |
The therapeutic effects of epinephrine may be diminished by beta-blockers (Beta1 Selective) (Racemic). |
|
EPINEPHrine (Systemic) |
Epinephrine's therapeutic impact may be reduced by beta-blockers (Beta1 Selective) (Systemic). |
|
Herbs (Hypertensive Properties) |
May lessen the effectiveness of antihypertensive agents. |
|
Herbs (Hypotensive Properties) |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Hypotension-Associated Agents |
The hypotensive action of hypotension-associated agents may be strengthened by blood pressure lowering medications. |
|
Insulins |
Beta-Blockers might improve insulin's ability to lower blood sugar. |
|
Ivabradine |
Bradycardia-Causing Agents may intensify Ivabradine's bradycardic impact. |
|
Ivosidenib |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). |
|
Lacosamide |
Bradycardia-Causing Substances may intensify Lacosamide's AV-blocking effects. |
|
Levodopa-Containing Products |
Levodopa-Containing Products' hypotensive effects may be strengthened by blood pressure-lowering medications. |
|
Lidocaine (Systemic) |
Beta-blockers might boost the level of lidocaine in the blood (Systemic). |
|
Lidocaine (Topical) |
Beta-blockers might boost the level of lidocaine in the blood (Topical). |
|
Lormetazepam |
The hypotensive effects of blood pressure-lowering medications may be strengthened. |
|
Mepivacaine |
Beta-Blockers may increase the serum concentration of Mepivacaine. |
|
Methoxyflurane |
May enhance the hypotensive effect of Beta-Blockers. |
|
Methylphenidate |
May diminish the antihypertensive effect of Antihypertensive Agents. |
|
Midodrine |
May enhance the bradycardic effect of Bradycardia-Causing Agents. |
|
Molsidomine |
May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
|
Naftopidil |
May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
|
Nicergoline |
May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
|
Nicorandil |
May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
|
NIFEdipine |
May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers. |
|
Nitroprusside |
Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. |
|
Nonsteroidal Anti-Inflammatory Agents |
May diminish the antihypertensive effect of BetaBlockers. |
|
Opioids (Anilidopiperidine) |
May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers. |
|
Pentoxifylline |
May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
|
Pholcodine |
Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. |
|
Phosphodiesterase 5 Inhibitors |
May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
|
Propafenone |
May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity. |
|
Prostacyclin Analogues |
May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
|
Quinagolide |
May enhance the hypotensive effect of Blood Pressure Lowering Agents. |
|
Regorafenib |
May enhance the bradycardic effect of Beta-Blockers. |
|
Reserpine |
May enhance the hypotensive effect of Beta-Blockers. |
|
Rifamycin Derivatives |
May decrease the serum concentration of Beta-Blockers. Exceptions: Rifabutin. |
|
Ruxolitinib |
May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible. |
|
Sarilumab |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). |
|
Siltuximab |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). |
|
Sulfonylureas |
Beta-Blockers might make Sulfonylureas' hypoglycemia effect more potent. Beta-blockers that are cardioselective (such penbutolol, acebutolol, atenolol, and metoprolol) may be less dangerous than nonselective beta-blockers. As the initial sign of hypoglycemia, tachycardia seems to be concealed by all beta-blockers. Beta-blockers used intravenously most likely carry a lesser risk than those used systemically. |
|
Terlipressin |
Bradycardia-Causing Agents' bradycardic effect might be enhanced. |
|
Theophylline Derivatives |
Theophylline derivatives may not have the same bronchodilatory action when used with beta-blockers (Beta1 Selective). Management: Keep an eye out for decreased theophylline effectiveness when using any beta-blocker at the same time. Compared to nonselective medicines, beta-1 selective drugs are less likely to antagonise theophylline, but selectivity may be lost at larger dosages. |
|
Tocilizumab |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). |
|
Tofacitinib |
May enhance the bradycardic effect of Bradycardia-Causing Agents. |
|
Yohimbine |
May diminish the antihypertensive effect of Antihypertensive Agents. |
|
Risk Factor D (Consider therapy modification) |
|
|
Alpha2-Agonists |
May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable. Exceptions: Apraclonidine. |
|
Amifostine |
Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered. |
|
Ceritinib |
|
|
CYP3A4 Inducers (Strong) |
May speed up CYP3A4 substrate metabolism (High risk with Inducers). Management: Take into account a substitute for one of the interfering medications. Specific contraindications may apply to some combinations. the relevant manufacturer's label. |
|
Dabrafenib |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). Management: When possible, look for substitutes for the CYP3A4 substrate. If concurrent therapy cannot be avoided, pay special attention to the substrate's clinical consequences (particularly therapeutic effects). |
|
Dronedarone |
May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in betablocker dose. |
|
Enzalutamide |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). Treatment: Enzalutamide should not be used concurrently with CYP3A4 substrates that have a limited therapeutic index. Enzalutamide use, like with the use of any other CYP3A4 substrate, should be done cautiously and under close observation. |
|
Ergot Derivatives |
Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. Exceptions: Nicergoline. |
|
Fingolimod |
Beta-Blockers may enhance the bradycardic effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and beta-blockers if possible. If coadministration is necessary, patients should have overnight continuous ECG monitoring conducted after the first dose of fingolimod. Monitor patients for bradycardia. |
|
Grass Pollen Allergen Extract (5 Grass Extract) |
Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine. Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. |
|
Lorlatinib |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). Management: Avoid taking lorlatinib at the same time as any CYP3A4 substrates for which even a small drop in serum levels of the substrate could result in therapeutic failure and negative clinical outcomes. |
|
Mitotane |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). Treatment: When administered in individuals receiving mitotane, doses of CYP3A4 substrates may need to be significantly modified. |
|
Obinutuzumab |
The hypotensive effects of blood pressure-lowering medications may be strengthened. Management: Take into account temporarily stopping blood pressure-lowering drugs 12 hours before the start of the obinutuzumab infusion and keeping them off until 1 hour after the infusion is finished. |
|
Pitolisant |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). Management: Pitolisant should not be used in conjunction with a CYP3A4 substrate that has a limited therapeutic index. When administered with pitolisant, other CYP3A4 substrates need to be checked more carefully. |
|
Siponimod |
Siponimod's bradycardic action may be enhanced by bradycardia-causing substances. Management: Steer clear of combining siponimod with medications that can slow your heart rate. |
|
St John's Wort |
May lower the serum level of CYP3A4 substrates (High risk with Inducers). Management: Take into account a substitute for one of the interfering medications. Specific contraindications may apply to some combinations. the relevant manufacturer's label. |
|
Risk Factor X (Avoid combination) |
|
|
Bromperidol |
The hypotensive impact of bromperidol may be enhanced by blood pressure lowering medications. Blood Pressure Lowering Agents' hypotensive effects may be lessened by bromperidol. |
|
Floctafenine |
May intensify the hazardous or harmful effects of beta-blockers. |
|
Methacholine |
Beta-Blockers might make methacholine's harmful or toxic effects worse. |
|
Rivastigmine |
Could make beta-blockers' bradycardic impact stronger. |
Monitor:
- Blood pressure
- Heart rate
- ECG
- Serum glucose in patients with diabetes.
Target Blood pressure:
- Target blood pressure of less than 130/80 mmHg in patients with hypertension and known cardiovascular disease or the 10-year ASCVD risk is greater than 10%.
- The target blood pressure of less than 130/80 mmHg may be reasonable in patients with ASCVD risk.
- Target blood pressure of less than 140/90 mmHg in patients aged 18 – 65 years with Diabetes and hypertension without cardiovascular disease and the 10-year ASCVD risk is less than 15%.
- Target blood pressure of less than 130/80 mmHg in patients aged 18 – 65 years with Diabetes, hypertension, cardiovascular disease, or the 10-year ASCVD risk is greater than 15%.
- Target blood pressure of less than 140/90 mmHg in patients aged more than 65 years and without major comorbid conditions.
- Target blood pressure of less than 150/90 mmHg in patients aged more than 65 years and poor health or comorbid conditions.
How to take Bisoprolol (Bisotrol)?
- It may be taken orally with or without regard to meals.
Mechanism of action of Bisoprolol (Bisotrol):
- It selectively inhibits Beta-1 receptors.
- It blocks Beta-1 receptors competitively, but has little to no effect on Beta-2 receptors when taken less than 20mg/day.
It is capable of initiating action at the rate ofIt takes between 1 and 2 hours. It is quickly absorbed completely and widely distributed throughout the body.
Concentrations higher than that are found in the liver, heart, lungs, saliva, and saliva. It crosses theBlood-brain barrierProtein-bound drugs account for 30% of drug's total weight. It is widely used.
Metabolized20% of the drug is first passed through the liver. It has been abioavailabilityOf 80%.
Bisoprololhalf-life eliminationPatients with normal renal function have a waiting time of 9-12 hours, patients with CrCl less than 40ml/min and patients with cirrhosis 8-22 hours.
TheTime to achieve peak effectIt can be seen in between 2 and 4 hours.excretedPrimarily in the urine
Bisoprolol brand names (International):
- APO-Bisoprolol
- MINT-Bisoprolol
- MYLAN-Bisoprolol
- PHL-Bisoprolol
- PMS-Bisoprolol
- PRO-Bisoprolol-10
- PRO-Bisoprolol-5
- RIntravenousA-Bisoprolol
- SANDOZ Bisoprolol
- TEVA-Bisoprolol
- Adroten
- Ancor
- B-Beta
- B-Cor
- Beprol
- Beta-One
- Betabis
- Betapro
- Bicard
- Bicor
- Bilocor
- Biol
- Bipro
- Biprolol
- Biscor
- Bisloc
- Biso
- Biso 5
- Bisoblock
- Bisocard
- Bisocor
- Bisohexal
- Bisol
- Bisolock
- Bisomerck
- Bisono Tape
- Bisop
- Bisopine
- Bisostad
- Bisosten
- Bisoten
- Bisotrol
- Bispro
- Biteven
- Bosvate
- Caprol
- Carbisol
- Cardensiel
- Cardex
- Cardiloc
- Cardiosafe
- Cobis
- Colber
- Concor
- Concor COR
- Concor-Cor
- Concore
- Corbis
- Corbloc
- Cordinorm
- Corentel
- Emconcor
- Euradal
- Hapsen
- Hypercor
- Isoten
- Jutabis
- Kenco
- Maintate
- Monocor
- Novacor
- Pactens
- Probis
- Sopalol
- Soprol
- Soprol-5
- Vasoten
- Zabesta
Bisoprolol Brand Names in Pakistan:
|
Bisoprolol (Fumarate) [Tabs 5 mg] |
|
| Actintramuscular | SAMI PHARMACEUTICALS (PVT) LTD. |
| Barilol | Barrett Hodgson Pakistan (Pvt) Ltd. |
| Biscord | Selmore Agencies |
| Biscot | Scotmann Pharmaceuticals |
| Bison | Siza International (Pvt) Ltd. |
| Bisprol | Kuratintravenouse Pak (Pvt) Ltd |
| Byso | Medizan Labs (Pvt) Ltd |
| Concor | Merck Printravenousate Ltd. |
| Corbis | Efroze Chemical Industries (Pvt) Ltd. |
| Monitor | Werrick Pharmaceuticals |
| Monocor | Standpharm Pakistan (Pvt) Ltd. |
| Probase | Mass Pharma (Printravenousate) Lintramuscularited |
| Safcor | Saffron Pharmaceutical Company |
| Sopral | Bryon Pharmaceuticals (Pvt) Ltd. |
| Valvozid | Pacific Pharmaceuticals Ltd. |
|
Bisoprolol (Fumarate) [Tabs 10 mg] |
|
| Actintramuscular | SAMI PHARMACEUTICALS (PVT) LTD. |
| Barilol | Barrett Hodgson Pakistan (Pvt) Ltd. |
| Biscord | Selmore Agencies |
| Biscot | Scotmann Pharmaceuticals |
| Bisprol | Kuratintravenouse Pak (Pvt) Ltd |
| Byso | Medizan Labs (Pvt) Ltd |
| Concor | Merck Printravenousate Ltd. |
| Corbis | Efroze Chemical Industries (Pvt) Ltd. |
| Monitor | Werrick Pharmaceuticals |
| Monocor | Standpharm Pakistan (Pvt) Ltd. |
| Probase | Mass Pharma (Printravenousate) Lintramuscularited |
| Safcor | Saffron Pharmaceutical Company |
| Sopral | Bryon Pharmaceuticals (Pvt) Ltd. |
| Valvozid | Pacific Pharmaceuticals Ltd. |
|
Bisoprolol (Fumarate) [Tabs 2.5 mg] |
|
| Actintramuscular | SAMI PHARMACEUTICALS (PVT) LTD. |
| Barilol | Barrett Hodgson Pakistan (Pvt) Ltd. |
| Concor | Merck Printravenousate Ltd. |
| Corbis | Efroze Chemical Industries (Pvt) Ltd. |
| Corbis | Efroze Chemical Industries (Pvt) Ltd. |
| Monitor | Werrick Pharmaceuticals |
| Safcor | Saffron Pharmaceutical Company |
| Sopral | Bryon Pharmaceuticals (Pvt) Ltd. |
 Injection.webp)